Professor of Pulmonary Medicine at the Univeristy of Montpellier. Former Director of the INSERM Laboratory for the Immunopathology of Asthma & former chairman of the Global Initiative for Asthma (GINA). Founder & Chairman of ARIA (Allergic Rhinitis & its Impact on Asthma). Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD). Former President of the Societé Française dAllergologie et dImmunologie Clinique. Former EiC of the journal Allergy.
Dr Vincenzo Brancaleone is Assistant Professor of Pharmacology, Dept. of Science, University of Basilicata.
He performs reviewer activity for international relevant and impacted scientific journal: Mediators of Inflammation (IF:3.263), British Journal of Pharmacology (IF:4.409), Inflammation Research (IF:2.109), Diabetes & Vascular Disease Research (IF:2.116), FasebJ (IF:5.299)
Dr. Brancaleone main research field includes: 1) vascular biology in vivo and in vitro in physiopathological conditions related to gaseous mediators: role of nitric oxide (NO) and hydrogen sulfide (H2S); 2) role of sphingosine-1-kinase/sphingosine-1-phosphate (S1PK/S1P) pathway in vascular, respiratory and inflammatory processes;
3) role of Annexin A1 and its receptor (Formylated Peptide Receptor 2, FPR2) in resolving mechanism in inflammation.
Dr. Brancaleone is full member of British Pharmacological Society (BPS) and Italian Society of Pharmacology (SIF).
Prof. of Immunology and Director of INSERM UMRS 940. Head of the 'Jean Dausset' Histocompatibility & Immunogenetics Laboratory at Saint-Louis Hospital. Former President of the International Histocompatibility council (IHC), former chairman of the 12th International Histocompatibility Workshop & Conference (IHWC) & former President of the European Foundation of Immunogenetics (EFI). Founder President of HLA & Medicine & founding member of the European Institute for System Biology & Medicine.
Head of Section, Allergy and Clinical Immunology at National Heart and Lung Institute, Imperial College and Honorary Consultant Physician in Allergy and Respiratory Medicine at Royal Brompton Hospital London. The immediate Past President of the British Society for Allergy and Clinical Immunology. Member Steering Committee and head of Allergy Consortium, Immune Tolerance Network/NIAID, USA.
Early studies (Oxford University) on DNA damage, DNA repair, mutagenesis in yeast. Current 50% Auckland Cancer Society Research Centre, Mutagenicity testing to predict carcinogenesis, 50% Discipline of Nutrition and Dietetics, The University of Auckland. Studies gene-diet interactions in the development of chronic disease (e.g. Inflammatory Bowel Disease, prostate cancer). 2004-2014, Programme leader of Nutrigenomics New Zealand, bringing nutrigenomics tools to food development in New Zealand.
Chairman of the Dept. of Pediatrics at National Jewish Health in Denver. Vice-Chairman of the Dept. of Pediatrics at the Univ. of Colorado Health Sciences Center. Recipient of the Mead Johnson Award for Research in Pediatrics, the McLaughlin Foundation Edward Gallie Professorship of the Royal College of Physicians and Surgeons of Canada, the Lifetime Achievement Award from National Jewish, and the Honorary Fellow Award from the American Academy of Allergy, Asthma and Immunology.
Professor of Pathology (retired), New York Medical College. Fellow, American Academy of Microbiology, New York Academy of Medicine.
Member, American Association of Immunologists, British Society for Immunology, American Society for Microbiology, New York Academy of Sciences, American Association for Science, Harvey Society.
Sandra Kleinau obtained her Ph.D. in clinical immunology from Uppsala University (UU), Sweden and performed postdoctoral studies at Karolinska Institute in Stockholm and later at UU. She established her own research group in 1997, received a permanent position at UU in 2004 and became Professor of Biology in 2008. Dr Kleinau has a research interest in autoimmunity, particularly autoimmune arthritis, with focus on exploiting B cells, antibodies, Fc receptors and complement.
Main research Interests:
A) Asthma is a major cause of morbidity in the Western world but curative therapies do not exist. Hence, we aim to understand how early life environmental exposures modify lung development development and the risk of developing asthma throughout life. We use animal models of prenatal exposure to tobacco/nicotine products and human samples.
B) The importance of a steady-state balance of resident and non-resident bacterial communities for human health is increasingly appreciated. Yet, factors driving the composition of such microbial communities remain poorly understood. Therefore, we currently investigate the influence of smoke on the structure and functionality of the lung microbiome and its interaction with the lung health.
Currently Funded Projects
2012 – 2016 Chair of COST Action BM1201 “Developmental origins of Chronic Lung Disease” http://www.cost-early-origin-cld.eu/
2013 – 2016 Understanding the role of the lung microbiome for human health and diseases”, HMGU Environmental Health Projects, Co-PI until move to University of Kiel; Project currently continued on a collaborative basis.
Since 2013 – 2018 PI within German Center for Lung Research www.dzl.de
2016 - 2018 Chair of “The lung Microbiota at the Interface between airway epithelium and the environment” funded by the Leibniz Association
Dr. Sushil Kumar is a Research Assistant professor at the Oregon Health & Science University (OHSU), Portland Oregon. He obtained his PhD from Max Planck Institute for biochemistry, Munich Germany where he worked in supervision of prof. Axel Ullrich for studying cancer cell signaling. He did his postdoctoral work in prof. Reto Schwendener’s laboratory at University of Zurich where he developed liposomal drugs for targeted delivery of payloads to macrophages as novel cancer therapy approach. He joined OHSU in 2012 in Prof. Lisa Coussens laboratory where he has continued his research for studying cancer inflammation and developing immunotherapeutic approaches for cancer. He is employing ex vivo as well as mouse models for understanding immune cell phenotype for analyzing their role in cancer progression and developing novel therapeutics as well as biomarkers for cancer.
Professor of Cutaneous Medicine, University of Manchester and Professor of Dermatology and Experimental Dermatology, University of Luebeck. Editor, Epxerimental Dermatology.
Carlo Pucillo is full professor in Immunology at School of Medicine of University of Udine. In his scientific career Prof. Carlo Pucillo has studied the "non canonical function" of MHC class II and the molecular mechanism that regulate the B cell activation and differentiation. From 2-1991 to 6-1994 Dr Pucillo has been Visiting Scientist at NCI in Bethesda, MD-USA.
He has acquired a considerable expertise in advanced molecular biology analysis as well as a good understanding of the immunobiology of the immune response, of the non canonical function of MHC class II molecules, in particular, as documented by his publications on this subjects.
He has also investigated the signal transduction pathways elicited by T-B cell interaction via CD40-CD154. CD40 is a B cell surface receptor that belongs to the pleiotropic tumor necrosis factor receptor (TNFR) superfamily. The interaction between CD40 and its ligand promotes proliferation, cytokine production, upregulation of various surface molecules involved in antigen presentation, germinal center and memory B cell formation antibody isotype switching and affinity maturation and the B cell life span.
Most recently, his interest is in the study of regulatory role of Mast Cells in the microenvironment and subsequently in the tissutal tolerance and adaptive immune response. This body of work may provide a conceptual framework to therapeutically manipulate these responses in the settings of autoimmune disease and cancer.